Celyad Oncology

Rue Edouard Belin 12
1435 Mont-Saint-Guibert
BE
Celyad Oncology
Foundation date
24/07/2007
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of CAR T therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.
Upcoming events
All events-
2809 '22
NLSDays 2022
Event by: SwedenBIO -
2809 '22
Neurotechnologies
Event by: VIB -
0712 '22
Emerging Applications of Microbes (2nd edition)
Event by: VIB
Latest news
More news-
Mayne Pharma and Mithra announce FDA approval of HALOETTE®, a generic version of NUVARING®
6 hours ago
Read more
-
S-Biomedic welcomes Pascal Yvon to lead its B2B commercial activities
Tuesday August 2nd 2022
Read more
-
Celyad Oncology announces FDA lifts clinical hold of CYAD-101-002 Phase 1b trial
Monday August 1st 2022
Read more
Jobs
More jobs-
-
08/08/22
Flemish Brabant
PhD Position in Optical Oxygen Mapping in Porous Biomaterials
Doctoral/PhD
KU Leuven -